China Biopharma, Boehringer Ingelheim Sign $7B Licensing Deal

The size of the headline figure matters less than the structure: this is an option-based, preclinical-stage arrangement, so the $7 billion reflects contingent milestones rather than committed capital, and the assets carry discovery risk before any value is realized. It signals continued appetite among large pharma for early-stage Chinese oncology pipelines, particularly ADCs and T-cell engagers, and puts the originating biotechs' ability to hand off programs to a global developer in focus. Whether similar option-heavy structures become the template for China-out licensing is the open question.